Table 1 Basic features of the publications included in this meta-analysis (n = 11)
First author | Year | Cancer type | Number of patients | SNHG5 expression | Referrence gene | Cut-off value | Survival analysis | HR statistics | Hazard ratios (95%CI) | Analysis method | Follow-up (month) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ma ZP | 2018 | Bladder cancer | 67 | Upregulated | GAPDH | Mean | OS | Survival curve | 2.82 (1.13–7.01) | Univariate analysis | 60 | 8 |
Li YR | 2018 | HCC | 48 | Upregulated | GAPDH | Median | OS | Paper | 4.74 (1.350–6.640) | Multivariate analysis | 36 | 8 |
RFS | 3.690 (1.229–11.082) | Multivariate analysis | 36 | 8 | ||||||||
Zhang LY | 2021 | CC | 40 | Upregulated | GAPDH | Median | Not reported | – | – | – | – | 7 |
Wang ZW | 2018 | Osteosarcoma | 32 | Upregulated | GAPDH | Median | OS | Survival curve | 7.52 (1.66–34.1) | Univariate analysis | 36 | 7 |
Liu DT | 2020 | Nasopharyngeal carcinoma | 64 | Upregulated | GAPDH | Median | OS | Survival curve | 1.57 (0.92–2.68) | Univariate analysis | 60 | 7 |
Wei SS | 2021 | Esophageal cancer | 77 | Upregulated | GAPDH | Median | OS | Survival curve | 0.42 (0.22–0.8) | Univariate analysis | 60 | 8 |
Xing XJ | 2022 | DLBCL | 90 | Upregulated | GAPDH | Mean | Not reported | – | – | – | – | 7 |
Zhao L | 2016 | GC | 87 | Upregulated | GAPDH | Median | OS | Survival curve | 0.59 (0.32–1.09) | Univariate analysis | 48 | 7 |
Li XY | 2021 | GC | 50 | Downregulated | β-actin | Median | OS | Paper | 4.890 (2.125–14.633) | Multivariate analysis | 15 | 8 |
Ying XY | 2019 | AML | 80 | Upregulated | GAPDH | Mean | OS | Survival Curve | 2.06 (1.19–3.59) | Univariate analysis | 60 | 7 |
Kang SY | 2023 | NSCLC | 86 | Upregulated | GAPDH | Median | Not reported | – | – | – | – | 7 |